ProCE Banner Activity

Imbokodo: Phase IIb Trial of Heterologous HIV-1 Vaccine Regimen Among Women in Sub-Saharan Africa at High Risk for HIV Infection

Slideset Download
Conference Coverage
Despite having a favorable safety profile, the heterologous Imbokodo HIV-1 vaccine regimen did not provide statistically significant protection against HIV-1 among younger women at high risk for HIV-1 acquisition in sub-Saharan Africa.

Released: February 17, 2022

Expiration: February 16, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare